[Skip to Content]
[Skip to Content Landing]
Views 202
Citations 0
Comment & Response
April 2018

Assessing Pharmaceutical Research and Development Costs—Reply

Author Affiliations
  • 1Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland
  • 2Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland
  • 3Center for Health Care Ethics, Oregon Health and Science University, Portland
  • 4Myeloma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Intern Med. 2018;178(4):588-589. doi:10.1001/jamainternmed.2017.8737

In Reply We thank DeMasi, as well as van de Gronde and Pieters, for their interest in our article1 estimating the research and development (R&D) spending to bring a single cancer drug to the US market and its revenue postapproval.

First, both DeMasi and van de Gronde and Pieters raise the question of whether our analysis includes companies who were more successful than average, which would lead us to underestimate R&D spending.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Limit 140 characters
Limit 3600 characters or approximately 600 words